GlassScriptPhysician profile
John L Hoang
NPI 1477924132
$1,428.16
in general payments reported to CMS, 2019-2025
13 companies · $83.75 in 2025
The $83.75 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $20.57 · 2022: $890 · 2023: $290 · 2024: $144 · 2025: $83.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $517.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $517.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bard Peripheral Vascular, INC. | $832.29 | 2022-2024 | Venclose Maven Catheter |
| Amgen INC. | $165.16 | 2023 | Otezla, Repatha |
| Boston Scientific Corporation | $124.93 | 2021-2022 | |
| Abbvie INC. | $65.36 | 2023 | |
| Glaxosmithkline, LLC. | $41.21 | 2024-2025 | Shingrix, Arexvy, Nucala |
| Novo Nordisk INC | $35.06 | 2022-2024 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $33.49 | 2023 | Spravato |
| Aimmune Therapeutics, INC. | $25.74 | 2025 | Zenpep |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.71 | 2023 | Jardiance |
| Medtronic, INC. | $22.97 | 2025 | Venaseal |
| Otsuka America Pharmaceutical, INC. | $20.59 | 2024 | Rexulti |
| Ani Pharmaceuticals, INC. | $18.78 | 2025 | Purified Cortrophin Gel |
| Xeris Pharmaceuticals, INC. | $16.87 | 2024 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Hoang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.